SEC Form 4 · accession 0001193125-26-299803
Syndax Pharmaceuticals Inc · SNDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael A Metzger
Officer — Chief Executive Officer · Director
Period of report
Jul 8, 2026
Accepted (ET)
Jul 9, 2026 · 4:54 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001395937
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 8, 2026 | M | 32,375 | $6.38 | A | 517,218 | D | |
| Common StockF2 | Jul 8, 2026 | S | 32,375 | $24.2402 | D | 484,843 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to buy)F3 | $6.38 | Jul 8, 2026 | M | 32,375 | A | — | Feb 6, 2029 | Common Stock | 32,375 | 0 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 1,564,551 options to purchase shares of common stock that are vested and immediately exercisable and a total of 813,949 options to purchase shares of common stock that have not yet vested.
- F2The sale prices ranged from $24.00 to $24.43
- F3This option is fully vested.